Corp 1000

: Coya Therapeutics stock gains on new data from Alzheimer’s study

Shares of Coya Therapeutics Inc. COYA gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a study of its investigational therapy COYA 301 in patients with mild to moderate Alzheimer’s disease. An open-label study in eight patients found a decrease in neuroinflammation following treatment with the therapy, the company said in a release. Coya previously reported that patients in the COYA 301 trial achieved a significant improvement in cognitive function.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

Previous post Millionaires are hoarding cash, betting on higher rates, CNBC survey says
Next post : Jack Daniel’s parent Brown-Forman stock gains after sales top expectations, amid strength in premium bourbons and RTDs